Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane

Pharmacogenetics and Genomics

Volumn 23, Issue 6, 2013, Pages 293-300

  D'avolio, Antonio ^a   De Francia, Silvia ^b   Basile, Vittoria ^b   Cusato, Jessica ^a   De Martino, Francesca ^b   Pirro, Elisa ^b   Piccione, Francesca ^b   Ardito, Arianna ^b   Zaggia, Barbara ^b   Volante, Marco ^c   Di Perri, Giovanni ^a   Terzolo, Massimo ^b  

^a Amedeo di Savoia Hospital   (Italy)

^b Biological Sciences ^*  (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

ABCB1; CYP2B6; Mitotane; Pharmacogenetic; Plasma concentration

Indexed keywords

CYTOCHROME P450 2B6; MITOTANE; MULTIDRUG RESISTANCE PROTEIN 1;

ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOW DRUG DOSE; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84879146971     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283606cb2     Document Type: Article

References (52)

1. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab 2006; 91:2027-2037.
2. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 2001; 25:914-926.
3. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: Clinical and laboratory observations. Cancer 2000; 88:711-736.
4. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis(parachlorophenyl)-1,1- dichloroethane (DDD or TDE). Arch Pathol (Chic) 1949; 48:387-394.
5. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 27:4619-4629.
6. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 2000; 33:1197-1200.
7. Hart MM, Reagan RL, Adamson RH. The effect of isomers of DDD on the ACTH-induced steroid output, histology and ultrastructure of the dog adrenal cortex. Toxicol Appl Pharmacol 1973; 24:101-113.
8. Kitamura S, Shimizu Y, Shiraga Y, Yoshida M, Sugihara K, Ohta S. Reductive metabolism of p,p0-DDT and o,p0-DDT by rat liver cytochrome P450. Drug Metab Dispos 2002; 30:113-118.
9. Thomson Reuters. MICROMEDEX healthcare series. New York, NY USA: Thomson Reuters; 2009.
10. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189-2197.
11. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p0-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984; 20:47-53.
12. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p0DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92:1385-1392.
13. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, et al. Plasma concentrations of o,p0DDD, o,p0DDA, and o,p0DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96:1844-1851.
14. Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 2002; 20:941-950.
15. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-2380.
16. Fassnacht M, Johanssen S, Fenske W,Weismann D, Agha A, Beuschlein F, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95:4925-4932.
17. Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010; 17:265-272.
18. Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2008; 15:221-226.
19. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112:963-970, discussion 70-71.
20. Schteingart DE, Motazedi A, Noonan RA, Thompson NW. Treatment of adrenal carcinomas. Arch Surg 1982; 117:1142-1146.
21. Ardito A, Al Ghuzian A, Fassnacht M, Daffara F, Leboulleux S,Wortmann S, et al. Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)? In: Bristol Bioscientifica, editors. 13th European Congress of Endocrinology. Rotterdam, The Netherlands: Bristol Bioscientifica 2011; p. 66.
22. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer 2008; 15:1043-1053.
23. Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159-1169.
24. Zhou X, Barber WH, Moore CK, Tee LY, Aru G, Harrison S, et al. Frequency distribution of cytochrome P450 3A4 gene polymorphism in ethnic populations and in transplant recipients. Res Commun Mol Pathol Pharmacol 2006; 119:89-104.
25. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895-931.
26. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 1991; 73:18-29.
27. Shabbir A, DiStasio S, Zhao J, Cardozo CP, Wolff MS, Caplan AJ. Differential effects of the organochlorine pesticide DDT and its metabolite p,p0-DDE on p-glycoprotein activity and expression. Toxicol Appl Pharmacol 2005; 203:91-98.
28. Papotti M, Libe R, Duregon E, Volante M, Bertherat J, Tissier F. The Weiss score and beyond-histopathology for adrenocortical carcinoma. Horm Cancer 2011; 2:333-340.
29. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8:163-169.
30. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, et al. Streptozocin and o,p0DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol 2000; 11: 1281-1287.
31. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002; 94:2333-2343.
32. Villa R, Orlandi L, Berruti A, Dogliotti L, Zaffaroni N. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. Int J Oncol 1999; 14:133-138.
33. Schteingart DE. Adjuvant mitotane therapy of adrenal cancer-use and controversy. N Engl J Med 2007; 356:2415-2418.
34. Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 2012; 42:521-525.
35. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-181.
36. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, et al. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol 2012; 74:134-140.
37. De Francia S, Pirro E, Zappia F, De Martino F, Sprio AE, Daffara F, et al. A new simple HPLC method for measuring mitotane and its two principal metabolites tests in animals and mitotane-treated patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 837:69-75.
38. Jeannesson E, Albertini L, Siest G, Gomes AM, Ribeiro V, Aslanidis C, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol 2007; 21:411-418.
39. Jeannesson E, Siest G, Bastien B, Albertini L, Aslanidis C, Schmitz G, et al. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin Chim Acta 2009; 403:198-202.
40. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994; 69:947-951.
41. Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol 2011; 7:323-335.
42. Faggiano A, Leboulleux S, Young J, Schlumberger M, Baudin E. Rapidly progressing high o,p0DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: Preliminary results. Clin Endocrinol (Oxf) 2006; 64:110-113.
43. Mauclere-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, et al. High-dose mitotane strategy in adrenocortical carcinoma: Prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol 2012; 166:261-268.
44. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000; 85:2234-2238.
45. Van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J, Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164:621-626.
46. Haas DW. Human genetic variability and HIV treatment response. Curr HIV/AIDS Rep 2006; 3:53-58.
47. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-292.
48. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab 2012; 98:161-171.
49. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75:585-591.
50. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010; 88:676-684.
51. Svard J, Spiers JP, Mulcahy F, Hennessy M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: Functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 2010; 55:536-549.
52. Siccardi M, D'Avolio A, Baietto L, Gibbons S, Sciandra M, Colucci D, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47:1222-1225. Technological Research